William D. Collins

Mr. Collins’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

• Relay Therapeutics in connection with:
  • its $57 million Series A financing
  • its $63 million Series B financing
  • its $400 million Series C financing
  • its $460 million initial public offering
• Thrive Earlier Detection Corp. in connection with:
  • its $110 million Series A financing
  • its $257 million Series B financing
• EQRx in connection with its $200 million Series A financing 
• Forma Therapeutics in connection with:
  • its $100 million Series D financing
  • its $319.3 million initial public offering
• Kymera Therapeutics in connection with:
  
  • its $30 million Series A financing
  • its $65 million Series B financing
  • its $102 million Series C financing
  • its strategic collaboration with Vertex Pharmaceutical
  • its multi-program strategic collaboration with Sanofi
  • its $200 million initial public offering
• ROME Therapeutics in its $50 million Series A financing
• Accent Therapeutics in its $63.5 million Series B financing
• Nimbus Therapeutics in connection with:
  • its multi-target strategic alliance with Celgene Corporation in immunology
  • the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences
  • its $43 million Series B financing
• Tango Therapeutics in connection with
  • its $55 million Series A financing
  • its $60 million Series B financing
  • its $50 million financing
• TCR² Therapeutics in connection with:
  • its $44.5 million Series A financing
  • its $125 million Series B Financing
  • its $75 million initial public offering
• Magenta Therapeutics in connection with
  • its $48.5 million Series A financing
  • its $50 million Series B financing 
  • its strategic collaborations with Novartis and BeTheMatch
  • its $100 million initial public offering
• Intellia Therapeutics in connection with:
  • its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology
  • its collaboration and license agreements with Novartis and Regeneron
  • its $124.2 million initial public offering
  • its $150 million follow-on public offering
• Obsidian Therapeutics in connection with:
  • its $49.5 million Series A financing
  • its strategic collaboration with Celgene Corporation
• Orionis Biosciences in its research collaboration and financing transaction with Novartis
• Disc Medicine in its $50 million Series A financing
• Casma Therapeutics in its $58.5 million Series A financing
• Celsius Therapeutics in its $65 million Series A financing
• Arkuda Therapeutics in its $44 million Series A financing

Company Representation and Capital Markets Transactions

• Amarin Corporation in its $195.3 million, $121.2 million, $87.5 million, and $56.1 million follow-on offerings, its $53 million PIPE offering, its $150 million 144A note offering, and a $118.7 privately negotiated note exchange
• AMAG Pharmaceuticals in numerous follow-on equity offerings, convertible note offerings and its high-yield bond offering, raising more than $1.4 billion in capital, transformative acquisitions and other strategic transactions 
• Bluebird bio in its $116.1 million initial public offering

Mergers and Acquisitions

• Rodin Therapeutics in its $950 million sale to Alkermes 
• Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb 
• Ocata Therapeutics in its sale to Astellas 
• Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
• Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
• ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions

Mr. Collins also represents leading life science venture capital and investment firms, including Atlas Venture, Third Rock Ventures and Deerfield, in connection with their portfolio investments and related matters.